Pregnancy outcomes in women with growth hormone deficiency
Por:
Vila, G, Akerblad, AC, Mattsson, AF, Riedl, M, Webb, SM, Hana, V, Nielsen, EH, Biller, BMK, Luger, A
Publicada:
1 nov 2015
Resumen:
Objective: To study pregnancies in a large group of patients with growth hormone deficiency and hypopituitarism; and to investigate potential factors determining pregnancy outcomes and pregnancy complications.
Design: We analyzed pregnancies reported in KIMS, the Pfizer International Metabolic Database, of adult patients with growth hormone deficiency treated with growth hormone.
Setting: Outpatient clinics.
Patient(s): A total of 201 pregnancies were reported: 173 in female patients and 28 in partners of male patients.
Intervention(s): Growth hormone replacement therapy (GHRT) was prescribed according to the local clinical practice.
Main Outcome Measure(s): Pregnancy outcomes (live births, gestational week at delivery, and birth weight), pregnancy complications, and their relationship to use of GHRT during pregnancy were analyzed with regression models.
Result(s): Two-thirds of women underwent fertility treatment to achieve pregnancy. Growth hormone replacement therapy was stopped before pregnancy in 7.5% of the female patients, as soon as pregnancy was confirmed in 40.1%, and at the end of the second trimester in 24.7% of the patients, whereas 27.6% continued GHRT throughout pregnancy. Birth of a healthy child was reported in 79% of the female pregnancies, nonelective abortions occurred mainly in the first trimester, and one fetal malformation (cystic hygroma) was diagnosed in the second trimester. Pregnancy outcomes and pregnancy complications were not related to GHRT treatment patterns, method of conception, or number of additional pituitary deficiencies.
Conclusion(s): These data on pregnancy outcomes in a large group of women with hypopituitarism revealed no relationship between GHRT regimens and pregnancy outcomes. (C) 2015 by American Society for Reproductive Medicine.
Filiaciones:
Vila, G:
Med Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, Vienna, Austria
Akerblad, AC:
Pfizer Endocrine Care, Sollentuna, Sweden
Mattsson, AF:
Pfizer Endocrine Care, Sollentuna, Sweden
Riedl, M:
Med Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, Vienna, Austria
Webb, SM:
Univ Autonoma Barcelona, Hosp St Pau, IIB St Pau, E-08193 Barcelona, Spain
Univ Autonoma Barcelona, Hosp St Pau, Ctr Invest Biomed Enfermedades Raras CIBER ER, Dept Med,Unidad 747,Serv Endocrinol, E-08193 Barcelona, Spain
Hana, V:
Charles Univ Prague, Fac Med 1, Dept Internal Med 3, Prague, Czech Republic
Nielsen, EH:
Aalborg Univ Hosp, Dept Endocrinol, Aalborg, Denmark
Biller, BMK:
Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
Luger, A:
Med Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, Vienna, Austria
Bronze
|